SG10201509919UA - Treatment of jak2-mediated conditions - Google Patents
Treatment of jak2-mediated conditionsInfo
- Publication number
- SG10201509919UA SG10201509919UA SG10201509919UA SG10201509919UA SG10201509919UA SG 10201509919U A SG10201509919U A SG 10201509919UA SG 10201509919U A SG10201509919U A SG 10201509919UA SG 10201509919U A SG10201509919U A SG 10201509919UA SG 10201509919U A SG10201509919U A SG 10201509919UA
- Authority
- SG
- Singapore
- Prior art keywords
- jak2
- treatment
- mediated conditions
- mediated
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41947610P | 2010-12-03 | 2010-12-03 | |
| US201161492485P | 2011-06-02 | 2011-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201509919UA true SG10201509919UA (en) | 2016-01-28 |
Family
ID=46171087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201509919UA SG10201509919UA (en) | 2010-12-03 | 2011-11-29 | Treatment of jak2-mediated conditions |
| SG2013042239A SG190950A1 (en) | 2010-12-03 | 2011-11-29 | Treatment of jak2-mediated conditions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013042239A SG190950A1 (en) | 2010-12-03 | 2011-11-29 | Treatment of jak2-mediated conditions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140073643A1 (ko) |
| EP (1) | EP2646029A4 (ko) |
| JP (2) | JP2013544260A (ko) |
| KR (1) | KR20130137011A (ko) |
| CN (2) | CN104473933A (ko) |
| AU (1) | AU2011335882B2 (ko) |
| BR (1) | BR112013013684A2 (ko) |
| CA (1) | CA2819560A1 (ko) |
| EA (1) | EA201390815A1 (ko) |
| MX (1) | MX2013006261A (ko) |
| NZ (1) | NZ611654A (ko) |
| SG (2) | SG10201509919UA (ko) |
| WO (1) | WO2012071612A1 (ko) |
| ZA (1) | ZA201304280B (ko) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214483B (zh) | 2005-12-13 | 2014-12-17 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶 |
| CN104030990B (zh) | 2007-03-12 | 2017-01-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
| KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 |
| EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| MX2015001269A (es) * | 2012-07-27 | 2015-05-08 | Novartis Ag | Prediccion de la respuesta al tratamiento con un inhibidor de jak/stat. |
| CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) |
| CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| WO2014161046A1 (en) * | 2013-04-04 | 2014-10-09 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating diseases characterized by excessive wnt signalling |
| EP3030227B1 (en) | 2013-08-07 | 2020-04-08 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| HUE041456T2 (hu) * | 2014-02-28 | 2019-05-28 | Incyte Corp | JAK1 inhibitorok myelodysplasiás szindrómák kezelésére |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
| WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| CN106316964B (zh) | 2015-06-26 | 2019-06-25 | 苏州泽璟生物制药股份有限公司 | 苯基氨基嘧啶化合物或其盐的多晶型物 |
| CN106316963B (zh) * | 2015-06-26 | 2021-06-08 | 苏州泽璟生物制药股份有限公司 | 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物 |
| WO2018031579A1 (en) | 2016-08-10 | 2018-02-15 | Gilead Sciences, Inc. | Momelotinib for treating of acvr1 -mediated diseases |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| PE20211310A1 (es) | 2018-01-30 | 2021-07-22 | Incyte Corp | Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento |
| CN109045040A (zh) * | 2018-03-12 | 2018-12-21 | 首都医科大学附属北京天坛医院 | Cyt387用于制备治疗神经胶质瘤的药物的应用 |
| JP2021519775A (ja) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療 |
| WO2020041466A1 (en) * | 2018-08-21 | 2020-02-27 | Sierra Oncology, Inc. | Platelet count-agnostic methods of treating myelofibrosis |
| AU2020207391A1 (en) * | 2019-01-10 | 2021-06-24 | Sumitomo Pharma Oncology, Inc. | ALK5 inhibitors for treating myelodysplastic syndrome |
| CA3166545A1 (en) * | 2020-01-29 | 2021-08-05 | Igor THEURL | Methods of using momelotinib to treat joint inflammation |
| CN111358791A (zh) * | 2020-03-13 | 2020-07-03 | 深圳百奥捷生物科技有限公司 | Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104030990B (zh) * | 2007-03-12 | 2017-01-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
| US20100310563A1 (en) * | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
| JP2011530517A (ja) * | 2008-08-05 | 2011-12-22 | ターゲジェン インコーポレーティッド | サラセミアを処置する方法 |
-
2011
- 2011-11-29 SG SG10201509919UA patent/SG10201509919UA/en unknown
- 2011-11-29 SG SG2013042239A patent/SG190950A1/en unknown
- 2011-11-29 JP JP2013541149A patent/JP2013544260A/ja active Pending
- 2011-11-29 CN CN201410578333.2A patent/CN104473933A/zh active Pending
- 2011-11-29 US US13/991,139 patent/US20140073643A1/en not_active Abandoned
- 2011-11-29 MX MX2013006261A patent/MX2013006261A/es not_active Application Discontinuation
- 2011-11-29 EP EP11845391.9A patent/EP2646029A4/en not_active Withdrawn
- 2011-11-29 CN CN2011800639895A patent/CN103370068A/zh active Pending
- 2011-11-29 WO PCT/AU2011/001551 patent/WO2012071612A1/en active Application Filing
- 2011-11-29 KR KR1020137017256A patent/KR20130137011A/ko not_active Application Discontinuation
- 2011-11-29 BR BR112013013684A patent/BR112013013684A2/pt not_active IP Right Cessation
- 2011-11-29 CA CA2819560A patent/CA2819560A1/en not_active Abandoned
- 2011-11-29 AU AU2011335882A patent/AU2011335882B2/en not_active Ceased
- 2011-11-29 NZ NZ611654A patent/NZ611654A/en unknown
- 2011-11-29 EA EA201390815A patent/EA201390815A1/ru unknown
-
2013
- 2013-06-11 ZA ZA2013/04280A patent/ZA201304280B/en unknown
-
2015
- 2015-08-13 JP JP2015159834A patent/JP2015212305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG190950A1 (en) | 2013-07-31 |
| MX2013006261A (es) | 2013-10-01 |
| AU2011335882B2 (en) | 2016-03-10 |
| CA2819560A1 (en) | 2012-06-07 |
| NZ611654A (en) | 2015-08-28 |
| EP2646029A1 (en) | 2013-10-09 |
| EP2646029A4 (en) | 2014-06-18 |
| JP2013544260A (ja) | 2013-12-12 |
| EA201390815A1 (ru) | 2013-12-30 |
| ZA201304280B (en) | 2014-08-27 |
| CN103370068A (zh) | 2013-10-23 |
| BR112013013684A2 (pt) | 2016-09-06 |
| WO2012071612A1 (en) | 2012-06-07 |
| CN104473933A (zh) | 2015-04-01 |
| JP2015212305A (ja) | 2015-11-26 |
| AU2011335882A1 (en) | 2013-05-02 |
| KR20130137011A (ko) | 2013-12-13 |
| US20140073643A1 (en) | 2014-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
| IL220876A0 (en) | Treatment of cardiac conditions | |
| PL2652193T3 (pl) | Obróbka | |
| ZA201301601B (en) | Treatment of diseases | |
| EP2613786A4 (en) | TREATMENT OF DISEASES | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| GB201000916D0 (en) | Treatment of biofilms | |
| GB0915515D0 (en) | Treatment of vasculoproliferative conditions | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| PL3581199T3 (pl) | Sposoby leczenia lub zmniejszania panikulopatii obrzękowo- zwłóknieniowo-stwardnieniowej | |
| GB201018147D0 (en) | Method of treatment | |
| ZA201207973B (en) | Treatment of gout | |
| IL256026B (en) | Treatment methods | |
| GB201003920D0 (en) | Method of treatment | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| ZA201102173B (en) | Treatment of water | |
| EP2522360A4 (en) | VACCINE FOR TAUTOPATHY TREATMENT | |
| GB201013573D0 (en) | Treatment | |
| ZA201207496B (en) | Treatment of chicory | |
| ZA201103007B (en) | Treatment of tantalium-and/or niobium-containing compounds | |
| ZA201207497B (en) | Treatment of chicory | |
| EP2585103A4 (en) | METHOD OF TREATMENT | |
| GB201018149D0 (en) | Method of treatment | |
| GB201020015D0 (en) | Method of treatment |